Theranos Overview
- Founded
- 2003
- Status
- Out of Business
- Employees
- 60
- Latest Deal Type
- Liquidation
Theranos General Information
Description
Developer of bio-monitoring systems designed to facilitate small-sample collection, testing and rapid communication of diagnostic information.The company's proprietary miniLab created an integrated infrastructure for real-time testing, decision making and individualized therapy, enabling laboratories to process early detection and intervention.
Contact Information
Primary Industry
Monitoring Equipment
Primary Office
- 1701 Page Mill Road
- Palo Alto, CA 94304
- United States
Theranos Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Bankruptcy: Liquidation | 05-Sep-2018 | 00000 | Completed | Out of Business | ||
| 9. Debt - General | 23-Dec-2017 | 00000 | 00000 | Completed | Generating Revenue/Not Profitable | |
| 8. Secondary Transaction - Private | 27-Mar-2017 | 00000 | Completed | Generating Revenue/Not Profitable | ||
| 7. Later Stage VC (Series C3) | 01-Oct-2015 | 00000 | 000.00 | Cancelled | Generating Revenue/Not Profitable | |
| 6. Later Stage VC (Series C2) | 04-Feb-2014 | 00000 | 00000 | 00.00 | Completed | Generating Revenue/Not Profitable |
| 5. Later Stage VC (Series C1) | 28-Mar-2013 | 0000 | 00000 | 00.000 | Completed | Generating Revenue/Not Profitable |
| 4. Later Stage VC (Series C1) | 08-Jul-2010 | 0000 | 000.00 | 00.000 | Completed | Generating Revenue/Not Profitable |
| 3. Later Stage VC (Series C) | 15-Nov-2006 | 000.00 | 000.00 | 00000 | Completed | Startup |
| 2. Early Stage VC (Series B) | 16-Feb-2006 | $9.1M | $16M | 0000 | Completed | Startup |
| 1. Early Stage VC (Series A) | 30-Mar-2005 | $6.95M | $6.95M | 000.00 | Completed | Startup |
Theranos Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C3 | 00,000,000 | 00.000000 | 000 | 000 | 00 | 000 | 0.000 | |
| Series C2 | 00,000,000 | 00.000000 | 000 | 000 | 00 | 000 | 00.000 | |
| Series C1 | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 0.000 | |
| Series C | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Series B | 54,162,965 | $0.000100 | $0.18 | $0.18 | 1x | $0.18 | 10.03% | |
| Series A | 46,320,045 | $0.000100 | $0.15 | $0.15 | 1x | $0.15 | 8.58% |
Theranos Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of bio-monitoring systems designed to facilitate small-sample collection, testing and rapid communication of d
Monitoring Equipment
Palo Alto, CA
60
As of 2018
00000
000000000000
00000
00000000
sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nos
0000000000 000000000
Austin, TX
00
As of 0000
00000
00000000000
00000
00000 00
abore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nis
0000000000 000000000
Saint Paul, MN
000
As of 0000
000.00
000000000 -
000.00
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialTheranos Competitors (6)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Everlywell | Venture Capital-Backed | Austin, TX | 00 | 00000 | 00000000000 | 00000 |
| 00000 0000000 | Venture Capital-Backed | Saint Paul, MN | 000 | 000.00 | 000000000 - | 000.00 |
| 000000 | Formerly VC-backed | Union City, CA | 000 | 000.00 | 000000&0 | 000.00 |
| 00000 00000000000 | Formerly VC-backed | Sydney, Australia | 00 | 000.00 | 00000000 | 000.00 |
| 00000000 000000 | Formerly VC-backed | York, United Kingdom | 00 | 000.00 | 00000000 | 000.00 |
Theranos Executive Team (18)
Theranos Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial